Placebo-IV

DRUG2 trials

Sponsors

Eli Lilly and Company, Allakos Inc.

Conditions

Alzheimer DiseaseChronic Spontaneous UrticariaHealthy Participants

Phase 1

A Study of LY3002813 in Participants With Alzheimer's Disease

CompletedNCT01837641

Eli Lilly and CompanyAlzheimer Disease

Start: 2013-05-03End: 2016-08-24Updated: 2024-10-04

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

CompletedNCT06072157

Allakos Inc.Chronic Spontaneous Urticaria, Healthy Participants

Start: 2023-08-28End: 2025-05-12Updated: 2025-06-03

Related Papers

O4‐08‐06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‐18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)

Alzheimer s & Dementia2016-07-0123 citations